ES2369547T8 - Procedimiento para el tratamiento de enfermedades humanas asociadas con un contenido elevado de ácido desoxirribonucleico en los espacios extracelulares de los tejidos y preparación médica para llevar a cabo dicho procedimiento. - Google Patents

Procedimiento para el tratamiento de enfermedades humanas asociadas con un contenido elevado de ácido desoxirribonucleico en los espacios extracelulares de los tejidos y preparación médica para llevar a cabo dicho procedimiento. Download PDF

Info

Publication number
ES2369547T8
ES2369547T8 ES06843990T ES06843990T ES2369547T8 ES 2369547 T8 ES2369547 T8 ES 2369547T8 ES 06843990 T ES06843990 T ES 06843990T ES 06843990 T ES06843990 T ES 06843990T ES 2369547 T8 ES2369547 T8 ES 2369547T8
Authority
ES
Spain
Prior art keywords
procedure
diseases associated
human diseases
extracellular spaces
deoxirribonucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06843990T
Other languages
English (en)
Other versions
ES2369547T3 (es
Inventor
Dmitry Dmitrievich Genkin
Viktor Veniaminovich Tets
Georgy Viktorovich Tets
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CLS Therapeutics Ltd
Original Assignee
CLS Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CLS Therapeutics Ltd filed Critical CLS Therapeutics Ltd
Application granted granted Critical
Publication of ES2369547T3 publication Critical patent/ES2369547T3/es
Publication of ES2369547T8 publication Critical patent/ES2369547T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES06843990T 2006-11-28 2006-11-28 Procedimiento para el tratamiento de enfermedades humanas asociadas con un contenido elevado del ácido desoxirribonucleico en los espacios extracelulares de los tejidos y preparación médica para llevar a cabo dicho procedimiento. Active ES2369547T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2006/000642 WO2008066403A1 (en) 2006-11-28 2006-11-28 Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method

Publications (2)

Publication Number Publication Date
ES2369547T3 ES2369547T3 (es) 2011-12-01
ES2369547T8 true ES2369547T8 (es) 2012-01-05

Family

ID=39468110

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06843990T Active ES2369547T3 (es) 2006-11-28 2006-11-28 Procedimiento para el tratamiento de enfermedades humanas asociadas con un contenido elevado del ácido desoxirribonucleico en los espacios extracelulares de los tejidos y preparación médica para llevar a cabo dicho procedimiento.

Country Status (9)

Country Link
US (1) US8871200B2 (es)
EP (1) EP2095825B8 (es)
JP (1) JP5372769B2 (es)
KR (1) KR20090087095A (es)
AT (1) ATE513557T1 (es)
ES (1) ES2369547T3 (es)
IL (1) IL199005A (es)
PL (1) PL2095825T3 (es)
WO (1) WO2008066403A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
EP1880733A4 (en) 2005-04-25 2009-08-12 Genkin Dmitry Dmitrievich METHOD FOR EXTENDING THE LIFE OF A HUMAN AND ANIMALS
EP2095825B8 (en) 2006-11-28 2012-03-28 CLS Therapeutics Limited Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
KR101399376B1 (ko) 2009-09-18 2014-05-27 아르끄마 프랑스 글리세린의 탈수 반응에 의한 아크롤레인 및/또는 아크릴산의 제조용 촉매 및 방법
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
NZ733912A (en) 2015-01-04 2023-04-28 Protalix Ltd Modified dnase and uses thereof
JP6745873B2 (ja) * 2015-05-22 2020-08-26 ドミトリエヴィッチ ゲンキン，ドミトリー 神経変性における治療標的としての細胞外ｄｎａ
CA2994356A1 (en) 2015-10-07 2017-04-13 Novozymes A/S Compositions comprising dnase polypeptides
WO2018197547A1 (en) 2017-04-25 2018-11-01 Lipoxen Technologies Limited Methods of treating diseases related to net formation with parenteral administration of polysialylated dnase i
EP3740581A4 (en) 2018-01-16 2021-10-27 CLS Therapeutics Limited TREATMENT OF DISEASES BY LIVER EXPRESSION OF AN ENZYME WITH DESOXYRIBONUCLEASE (DNASE) ACTIVITY
EP3813555A4 (en) * 2018-06-29 2022-03-30 Tets, Viktor, Veniaminovich COMPOSITIONS FOR MODULATION OF INTESTINAL FLORA
US20200046809A1 (en) * 2018-08-07 2020-02-13 Bradley G. Thompson Methods for regulating endogenous production of dnase1
CA3149789A1 (en) * 2018-12-17 2020-06-25 Dennis C. Mynarcik Compositions and methods for removing dental calculi
WO2022074656A1 (en) 2020-10-07 2022-04-14 Protalix Ltd. Long-acting dnase

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3224942A (en) 1962-01-15 1965-12-21 Rorer Inc William H Anti-inflammatory, anti-edema and anti-thrombi drug
US3324002A (en) 1962-09-17 1967-06-06 Armour Pharma Anti-inflammatory preparations containing proteolytic enzymes and adrenal glucocorticoids
JPS5826822A (ja) 1981-08-10 1983-02-17 Kaken Pharmaceut Co Ltd 慢性腎炎治療剤
JPS61293927A (ja) * 1986-06-18 1986-12-24 Kaken Pharmaceut Co Ltd 肝臓疾患予防治療剤
US4985243A (en) 1988-01-20 1991-01-15 Ml Technology Ventures, L.P. Composition and method for protecting against diseases caused by microorganisms
ATE358176T1 (de) 1988-12-23 2007-04-15 Genentech Inc Menschliche dnase
US5464817A (en) 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
DE4024530A1 (de) 1990-08-02 1992-02-06 Klinger & Co Dr Verfahren zur bekaempfung von viren
FR2666096B1 (fr) 1990-08-21 1993-12-31 Sfri Sa Nouveau procede de dosage d'acide desoxyribonucleique present en position extracellulaire dans un milieu.
EP0599850B1 (en) 1991-08-16 1996-01-10 Vical, Inc. Composition and method for treating cystic fibrosis
US5484589A (en) * 1992-04-20 1996-01-16 Rufeld, Inc. Anti-viral methods using RNAse and DNAse
NZ299257A (en) 1992-06-08 2000-08-25 Genentech Inc Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase
WO1995000170A1 (en) 1993-06-24 1995-01-05 Rufeld, Inc. Inhibition of human immunodeficiency virus reproduction by deoxyribonuclease i
CH686982A5 (fr) 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
RU2099080C1 (ru) 1994-02-11 1997-12-20 Дмитрий Иванович Финько Способ предотвращения развития рака
JP2986215B2 (ja) 1994-03-04 1999-12-06 ジェネンテック インコーポレイテッド Ｄｎアーゼ含有医薬製剤
WO1995032219A1 (fr) 1994-05-20 1995-11-30 Hisamitsu Pharmaceutical Co., Inc. Proteine ou polypeptide, procede et intermediaires permettant leur preparation
DE69736276T2 (de) 1996-02-05 2007-08-30 Genentech Inc., San Francisco Menschliche dnase resistent gegen actininhibitoren
AU2324997A (en) 1996-03-15 1997-10-01 Penn State Research Foundation, The Detection of extracellular tumor-associated nucleic acid in blood plasma or ser um using nucleic acid amplification assays
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US6524578B1 (en) 1996-07-10 2003-02-25 Scott E. Tackett Use of nuclease to reduce wrinkles and discolorations in humans
US6455250B1 (en) 1997-12-11 2002-09-24 The Regents Of The University Of California Endonuclease compositions and methods of use
CA2337517A1 (en) 1998-07-16 2000-01-27 Research Development Foundation Novel dna-cleaving antitumor agents
US6465177B1 (en) 1998-10-26 2002-10-15 John Wayne Cancer Institute Detection of loss of heterozygosity in tumor and serum of melanoma patients
JP2002530436A (ja) 1998-11-25 2002-09-17 ジェネティカ インコーポレイテッド 増殖能を増強しかつ複製老化を防止する方法及び試薬
JP4522632B2 (ja) * 1999-08-17 2010-08-11 靖一 田沼 新規デオキシリボヌクレアーゼ、それをコードする遺伝子およびそれらの用途
US6428785B1 (en) 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
UA78486C2 (uk) 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
WO2001074905A1 (en) 2000-04-03 2001-10-11 Antisoma Research Limited Compounds for targeting
RU2202109C1 (ru) 2001-08-03 2003-04-10 Научно-исследовательский институт неврологии РАН Способ выявления степени нарушения реологических свойств крови
RU2207876C1 (ru) 2001-11-08 2003-07-10 Ткаченко Виталий Васильевич Способ комплексно-индивидуализированного воздействия на организм при медленной вирусной инфекции и способ подготовки лабораторного животного для испытания способа такого воздействия
DK1549337T3 (en) * 2002-02-18 2014-11-24 Ockham Biotech Ltd COMBINATION OF DNASE I AND GLYCOSAMINOGLYCANES FOR USE IN EXTRACELLULAR DNA CLEARANCE
RU2207676C1 (ru) 2002-04-24 2003-06-27 ООО "Предприятие "Контакт-1" Плоский радиолокационный отражатель
DE10221194B4 (de) 2002-05-13 2005-02-10 Fryda, Waltraud, Dr.med. Hyaluronidasehaltiges Hautpflegemittel
US20040001817A1 (en) 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
RU2239442C1 (ru) 2003-05-05 2004-11-10 Красноярская государственная медицинская академия Способ профилактики внутриутробных инфекций у детей
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
WO2005007187A1 (fr) 2003-07-14 2005-01-27 Viktor Veniaminovich Tets Methode de traitement des maladies oncologiques, infectieuses et somatiques, procedes de controle de l'efficacite du traitement, agents et compositions pharmaceutiques associes
WO2005004904A1 (fr) 2003-07-14 2005-01-20 Dmitry Dmitrievich Genkin Methode de traitement de maladies s'accompagnant d'alterations de la composition qualitative et/ou quantitative de l'adn extracellulaire du sang (variantes)
RU2269358C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения генерализованных инфекций, вызываемых бактериями, или заболеваний, вызываемых грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, обусловленных мутациями генов соматических клеток
RU2269359C2 (ru) 2004-03-12 2006-02-10 Дмитрий Дмитриевич Генкин Способ профилактики развития онкологических заболеваний или инфекций, вызываемых бактериями, грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, развивающихся вследствие мутации генов соматических клеток (варианты)
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
RU2269356C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения онкологических заболеваний
RU2239404C1 (ru) 2003-09-17 2004-11-10 Бессонов Дмитрий Михайлович Способ профилактики старения организма человека
RU2269357C2 (ru) 2004-03-12 2006-02-10 Дмитрий Дмитриевич Генкин Способ замедления наступления болезненных состояний, связанных с увеличением возраста человека
RU2267329C2 (ru) 2004-03-12 2006-01-10 Дмитрий Дмитриевич Генкин Способ лечения заболеваний, сопровождающихся изменениями качественного и/или количественного состава внеклеточной днк крови (варианты)
WO2005115444A2 (en) * 2004-04-14 2005-12-08 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
JP3989936B2 (ja) * 2005-04-07 2007-10-10 進 須永 抗腫瘍剤及び新規ｄｎアーゼ
EP1880733A4 (en) 2005-04-25 2009-08-12 Genkin Dmitry Dmitrievich METHOD FOR EXTENDING THE LIFE OF A HUMAN AND ANIMALS
WO2007010533A2 (en) * 2005-07-18 2007-01-25 Protalix Ltd. Mucosal or enteral administration of biologically active macromolecules
RU2308968C2 (ru) 2005-07-19 2007-10-27 Дмитрий Дмитриевич Генкин Способ лечения заболеваний человека, сопровождающихся повышенным содержанием дезоксирибонуклеиновой кислоты во внеклеточных пространствах тканей, и лекарственный препарат для его реализации
WO2008047364A2 (en) 2006-10-18 2008-04-24 Periness Ltd. Method and pharmacological composition for the diagnosis and treatment of male sub-fertility
EP2095825B8 (en) 2006-11-28 2012-03-28 CLS Therapeutics Limited Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
GB0922006D0 (en) 2009-12-17 2010-02-03 Genome Res Ltd Diagnostic
US20130243794A1 (en) 2010-12-03 2013-09-19 Beth Israel Deaconess Medical Center, Inc. Methods for predicting and treating infection-induced illnesses and predicting the severity of infection-induced illnesses

Also Published As

Publication number Publication date
EP2095825A4 (en) 2009-12-30
WO2008066403A1 (en) 2008-06-05
PL2095825T3 (pl) 2011-12-30
ES2369547T3 (es) 2011-12-01
US8871200B2 (en) 2014-10-28
US20100061971A1 (en) 2010-03-11
EP2095825B8 (en) 2012-03-28
KR20090087095A (ko) 2009-08-14
JP2010511039A (ja) 2010-04-08
IL199005A0 (en) 2010-02-17
IL199005A (en) 2012-04-30
ATE513557T1 (de) 2011-07-15
EP2095825B1 (en) 2011-06-22
JP5372769B2 (ja) 2013-12-18
EP2095825A1 (en) 2009-09-02

Similar Documents

Publication Publication Date Title
ES2369547T8 (es) Procedimiento para el tratamiento de enfermedades humanas asociadas con un contenido elevado de ácido desoxirribonucleico en los espacios extracelulares de los tejidos y preparación médica para llevar a cabo dicho procedimiento.
CN110151594A (zh) 一种含依克多因和透明质酸的口腔组合物及其应用
JP2006501240A5 (es)
AR065579A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
BRPI0510862A (pt) medicamento para tratar disfunção sexual em um paciente, medicamento para tratar disfunção erétil em um paciente, medicamento para diminuir os efeitos colaterais associados com os agentes terapêuticos para tratar a disfunção sexual em um paciente, método para fabricação de um medicamento para tratamento da disfunção sexual de um paciente responsivo marginalmente ao inibidor de pde5, e uso do peptìdeo ac-nle-ciclo (-asp-his-d-phe-arg-trp-lys) -0h na perparação de um medicamento
AR065580A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
MX358492B (es) Suministro intraventricular lento.
PL2043637T3 (pl) Sposoby i leki do podawania ibuprofenu
WO2008025790A3 (en) Use of opioid formulations in needle-less drug delivery devices
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
Zhao et al. Anti-arthritic effects of microneedling with bee venom gel
DE602005021115D1 (de) Verfahren und zusammensetzungen zur oralen fts-abgabe
BRPI0415215B8 (pt) uso de polifenol na preparação de medicamento
WO2014176417A1 (en) Topical preparation for bypassing gi tract, delivery of therapeutics, and trans-epithelial drug delivery system
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
MX2008015323A (es) Composicion farmaceutica que comprende ciclobenzaprina y aceclofenac en asociacion.
US20090036541A1 (en) Applicator and chemical combination for better topical anesthesia
CN102764412B (zh) 一种治疗小儿厌食、营养不良的中药组合物
US20190110512A1 (en) Food composition for relieving symptoms of viral diseases
RU2402356C1 (ru) Способ лечения гастроэзофагеальной рефлюксной болезни у детей
CN100560079C (zh) 一种用于治疗痔疮的中药针剂
CN102232968A (zh) 治疗脂溢性皮炎的中药外用药酒
CN101167878A (zh) 一种治疗关节炎的药物及其制备方法
CN100389810C (zh) 一种治疗痤疮的药物